CAS: 17082-61-0; 1,2-Bis((Trimethylsilyl)Oxy)Cyclobut-1-Ene

相似化合物

361-82-0 144791-02-6 3183-44-6

上下游产品

CAS号75-77-4 三甲基氯硅烷 | CAS号123-25-1 丁二酸二乙酯 | CAS号106-65-0 琥珀酸二甲酯 | CAS号142421-78-1 4-acetyl-7a-met... | CAS号4220-66-0 4,4-二甲氧基丁酸甲酯 | CAS号31411-71-9 2,3-双(三甲基甲硅烷氧基)... | CAS号823-36-9 2-乙基-1,3-环戊二酮 | CAS号705-15-7 2'-羟基-5'-甲氧基苯乙酮 | CAS号72229-70-0 2-(β-carboxyeth... | CAS号72229-59-5 cis-1-oxo-3a-hy... | CAS号72229-57-3 2-methyl-2-(2-a... | CAS号765-69-5 2-甲基-1,3-环戊二酮 | CAS号54966-52-8 ethyl 4-cyclohe...

己二酸二乙酯置于na On Poly(Ethylene) Support体系中,用 甲苯 用作溶剂,化学反应 2.0H,以70%的收率获得二(三甲基硅氧基)环丁烯
参考文献:Convenient Preparation Of 'High-Surface Sodium' In Liquid Ammonia: Use In The Acyloin Reaction
标题:Convenient Preparation Of 'High-Surface Sodium' In Liquid Ammonia: Use In The Acyloin Reaction
摘要:负载在固体上的钠(nacl含量为5-20 Wt.%,载体为玻璃粉,聚乙烯和聚丙烯)可以通过在液氨中低温(-33oc)沉积钠的方法方便地制备.在羧酸酯的乙酰化反应中使用该试剂,可以得到高产率的相应产物.
Doi:10.1055/s-1997-763

专利信息

专利号:US-5414074-A
优先权日:1992-09-25
标题:Synthesis of C-glycosylated compounds with the use of a mild, iodine-catalyzed reaction
发明人：KOREEDA MASATO; HOUSTON TODD A
权利人:UNIV MICHIGAN
摘要:The invention concerns C-glycosylated derivatives of soft carbon nucleophile compounds, particularly compounds which contain acid-labile structural units. The invention further concerns a mild, cost-effective, non-hazardous and stereoselective method of general application employing a glycal as a glycosyulating agent and iodine as a catalyst for the preparation of C-glycosylated soft carbon nucleophile compounds.

专利号:WO-9407899-A1
优先权日:1992-09-25
标 题:Synthesis of c-glycosylated compounds with the use of a mild, iodine-catalyzed reaction

专利号:US-11286268-B1
优先权日:2019-07-02
标题:EIF4E-inhibiting compounds and methods
发明人：SPERRY SAMUEL; XIANG ALAN X; ERNST JUSTIN T; REICH SIEGFRIED H; SPRENGELER PAUL A; SHAGHAFI MIKE; MICHELS THEO; NILEWSKI CHRISTIAN; TRAN CHINH VIET; PACKARD Garrick Kenneth; GRUBBS ALAN; URKALAN KAVERI; MUKAIYAMA TAKASUKE
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n n n n n n n n n n For Formula I compounds X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , Q, L 1 , L 2 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.